Navigation Links
New Drug Boosts 'Good' Cholesterol in Study Patients
Date:9/13/2011

TUESDAY, Sept. 13 (HealthDay News) -- A treatment currently being studied may prevent progression of atherosclerosis, a condition caused by the build-up of plaque in artery walls that can lead to heart attack, according to new research.

In conducting the study, published in the Sept. 12 issue of The Lancet, researchers followed 130 patients with atherosclerosis who were randomly assigned to be treated with either the experimental heart drug dalcetrapib, or an inactive placebo over the course of two years. In the double-blind study, neither the researchers nor the patients knew who was taking the heart drug and who was taking the placebo.

While statin drugs are commonly used to lower LDL or "bad" cholesterol to reduce the risk of coronary artery disease, dalcetrapib raises HDL or "good" cholesterol in order to reduce the risk, the researchers explained.

To determine the efficacy of dalcetrapib, the researchers used non-invasive imaging technology. Through MRI, the researchers found the patients on dalcetrapib had a 31 percent increase in "good" HDL cholesterol levels. Additional PET/CT scans showed that inflammation levels in the carotid artery of patients were significantly reduced only among those taking dalcetrapib. The carotid arteries are responsible for supplying oxygenated blood to the head and neck.

In a different study, a drug in the same class designed to raise HDL levels was tied to an increase in death linked to vascular inflammation, but the researchers did not find an increase in such inflammation with dalcetrapib.

"This milestone study shows that MRI and PET/CT are highly useful in assessing the safety and efficacy of dalcetrapib, and that this novel therapy may address a significantly unmet need in cardiovascular disease," said lead study author Zahi A. Fayad, a professor of radiology and medicine in the cardiology division at Mount Sinai School of Medicine and the director of its Translational and Molecular Imaging Institute, in a Mt. Sinai news release.

"We are excited about the results obtained in this trial, which could have a great impact on the treatment of patients with cardiovascular disease," said Fayad, who disclosed receiving financial compensation as a scientific advisory board member from the study's sponsor, Hoffmann-La Roche, whose holding company makes dalcetrapib.

Fayad noted imaging technology could be a vital tool for evaluating other treatments for heart disease.

More information

The U.S. National Library of Medicine has more about atherosclerosis.

-- Mary Elizabeth Dallas

SOURCE: Mount Sinai Hospital, news release, Sept. 12, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. TNF Treatment for Rheumatoid Arthritis Boosts Skin Cancer Risk
2. Regular Exercise Boosts the Brain, Too
3. Yoga boosts stress-busting hormone, reduces pain: York U study
4. Stopping Daily Aspirin Boosts Heart Attack Risk: Study
5. Study: Potassium Boosts Heart Health, Salt Harms It
6. Even One Glass of Beer, Wine Boosts Car Crash Risk: Study
7. Mystery ingredient in coffee boosts protection against Alzheimers disease
8. On-the-Job Activity Boosts Americans Exercise Levels
9. Weight Loss in Heavy, Obese Women Boosts Vitamin D Levels
10. Losing more than 15 percent of body weight significantly boosts vitamin D levels in overweight women
11. Tai Chi Prevents Falls, Boosts Mental Health in Seniors: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Boosts 'Good' Cholesterol in Study Patients
(Date:2/23/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Beach to host its Swirl: Miami Wine Tasting Event on March 28, 2017. ...
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Los ... two episodes of WE TV’s “Mama June: From Not to Hot,” which will begin ... notable, “Mama” June Shannon, known to millions from the 2012 reality television series, “Here ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... content provider for the National Institute for Health and Care Excellence ... organizations in the National Health Service (NHS) to search, order and purchase medical ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... exciting, new, interactive publication where generations converge and explore the world from different ... worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and find greater ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & ... in the fight against cancer, has produced a seminal study that asked cancer ... release top-line findings in a webinar, Defining Compassionate Care Through the Voices of ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017  Genesis Healthcare Services has merged with Hospice ... by Bill Monast , President and CEO of ... Nathan Feltman , executives with Home Health Depot, Inc., ... This acquisition helps Hospice Cloud maintain its ... durable medical equipment (DME) solutions for the hospice industry. ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... offering. ... Menopause Drugs Price Analysis and Strategies - 2016, provides drug pricing data ... following questions: What are the key drugs ... the Global Menopause market? What are the unit prices ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
Breaking Medicine Technology: